Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Intensive new combination therapy for ovarian cancer shows promising results

Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.

30 Sep 2019

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019

Scientists use advanced imaging to track brain tumor 'turncoats'

Glioblastomas, the deadliest type of brain tumor in adults, attract "turncoats." These are macrophages, a type of immune cell, which promote tumor progression and mask tumors from the immune system's scrutiny.

26 Jun 2019

Identifying colorectal cancer subtypes in patients could help provide better care

Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.

12 Jun 2019

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

12 Jun 2019

New study finds almost 400 established medical practices that don’t work

A new study set out to explore what does and does not work in the field of modern medical practice, and came up with 396 reported reversals of previously accepted medical practice over the last few decades.

12 Jun 2019

New analysis reveals precision oncology insights for colorectal cancer

Next-generation sequencing of tumor DNA from patients with colorectal cancer revealed genetic alterations that were linked to different survival and treatment outcomes in an analysis led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher.

20 Mar 2019

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

22 Oct 2018

Immunotherapy medicine found to be effective in treating uveitis

A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in ophtalmology, to treat uveítis, thus stopping the inflammation from spreading.

19 Oct 2018

Chromosomal instability may predict which patients will respond better to colorectal cancer drug

Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).

10 Oct 2018

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma -- an aggressive form of brain cancer with veryhttps://www.rush.edu/news/press-releases/rush-testing-new-brain-cancer-vaccine few current treatment options.

14 Sep 2018

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.

27 Aug 2018

Saving sight of millions by making eye injections safe and comfortable

Two eye surgeons have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections safe and comfortable.

7 Aug 2018

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration.

20 Jul 2018

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.

26 Jun 2018

Researchers explore targeted second-line treatment for colorectal cancer

Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction.

5 Jun 2018

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Pulmonary vein stenosis (PVS) is a rare disease in which abnormal cells build up inside the veins responsible for carrying oxygen-rich blood from the lungs to the heart. It restricts blood flow through these vessels, eventually sealing them off entirely if left untreated.

11 May 2018

Ludwig scientists develop and test individualized ovarian cancer vaccine

A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.

11 Apr 2018

Bevacizumab News and Research

Further Reading

Intensive new combination therapy for ovarian cancer shows promising results

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Scientists use advanced imaging to track brain tumor 'turncoats'

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

New study finds almost 400 established medical practices that don’t work

New analysis reveals precision oncology insights for colorectal cancer

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

Immunotherapy medicine found to be effective in treating uveitis

Chromosomal instability may predict which patients will respond better to colorectal cancer drug

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Saving sight of millions by making eye injections safe and comfortable

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

Researchers explore targeted second-line treatment for colorectal cancer

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Ludwig scientists develop and test individualized ovarian cancer vaccine

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News